Victory Capital Management Inc. Makes New $676,000 Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Victory Capital Management Inc. purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 19,152 shares of the company’s stock, valued at approximately $676,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Concurrent Investment Advisors LLC acquired a new position in Dyne Therapeutics during the 1st quarter worth about $573,000. Sei Investments Co. acquired a new position in shares of Dyne Therapeutics in the first quarter worth approximately $693,000. Rafferty Asset Management LLC boosted its holdings in Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after acquiring an additional 24,632 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $810,000. Finally, Commodore Capital LP bought a new position in Dyne Therapeutics during the 4th quarter worth approximately $11,970,000. 96.68% of the stock is currently owned by institutional investors.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the transaction, the insider now owns 140,375 shares of the company’s stock, valued at $4,849,956.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,339 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $80,812.45. Following the completion of the sale, the insider now directly owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,256,821.36. The disclosure for this sale can be found here. Insiders sold a total of 22,868 shares of company stock valued at $796,760 over the last three months. Corporate insiders own 20.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Piper Sandler increased their price target on Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Stifel Nicolaus raised their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, JPMorgan Chase & Co. lifted their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $36.59 on Friday. The stock has a market capitalization of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $47.45. The stock has a 50 day moving average price of $41.07 and a two-hundred day moving average price of $33.61.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. Research analysts forecast that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.